Zoldonat 4mg Injection contains Zoledronic acid 4mg, a potent bisphosphonate indicated for the treatment and prevention of bone-related conditions. It is primarily used to manage hypercalcemia of malignancy, reduce skeletal-related events in patients with bone metastases from solid tumors, and treat Paget’s disease of bone. Zoledronic acid acts by inhibiting osteoclast-mediated bone resorption, thereby stabilizing bone structure and reducing calcium release into the bloodstream. The injection is administered intravenously, typically as a single dose or repeated at intervals depending on the clinical indication and patient response. Zoldonat 4mg Injection requires careful monitoring of renal function prior to and during treatment, as zoledronic acid is contraindicated in patients with severe renal impairment. Adequate hydration before administration is recommended to minimize renal toxicity. Common adverse effects include flu-like symptoms, hypocalcemia, and transient renal function changes. Patients should be supplemented with calcium and vitamin D to prevent hypocalcemia. Caution is advised in patients with pre-existing dental conditions due to the risk of osteonecrosis of the jaw. Zoldonat 4mg Injection should be used under strict medical supervision, with dosing tailored to the specific clinical scenario to maximize therapeutic benefits while minimizing risks.